![]() Prior to joining Alumis, he was Chief Business Officer of Principia Biopharma where he negotiated Principia’s core collaborations with Sanofi and AbbVie. Roy Hardiman is our Chief Business Officer and general counsel, with over 30 years of business development, legal, alliance management and strategic experience in the biopharmaceutical field. ![]() Martin received a Swiss Federal Diploma in Pharmacy from the Federal Institute of Technology in Zurich and completed the Executive Development Program at the Kellogg Graduate School of Management at Northwestern University. He presently serves on the Board of Directors of Neoleukin Therapeutics, Inc., Prelude Therapeutics Inc., Omega Alpha SPAC, Sardona Therapeutics and on the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization. Martin previously served at Eli Lilly and Company in positions focused on sales, sales management, global marketing, and business development. While at Genentech, he also helped to build and led the Commercial Development organization and led the Cardiovascular Marketing organization. From 1998 to 2007, he held several positions at Genentech, Inc., most notably as Vice President, Immunology Sales and Marketing. ![]() Prior to joining Principia Biopharma, Martin served as President and Chief Executive Officer of Talima Therapeutics from 2007 to 2011. Prior to joining Alumis, he served as President and Chief Executive Officer of Principia Biopharma, until its acquisition by Sanofi S.A. Martin Babler is our Chief Executive Officer, President and Chairman of our Board since September 2021.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |